医疗补助扩展与切除梅克尔细胞癌患者的生存率提高有关:国家癌症数据库分析
Yingjoy Li1, Sarah W Yuen2, Tu Tran2
1University of California, Irvine School of Medicine, 1001 Health Sciences Rd, Irvine, CA 92697, U.S.A.
Journal of the American Academy of Dermatology
|December 31, 2025
概括
医疗补助扩展 (ME) 改善了默克尔细胞癌 (MCC) 患者的存活率,即使是那些疾病晚期的患者. 扩大保险覆盖面对及时的癌症治疗和低收入人群更好的结果至关重要.
科学领域:
- 在瘤学瘤学.
- 卫生政策 卫生政策
- 流行病学 流行病学
背景情况:
- 医疗补助扩张 (ME) 旨在增加低收入人群获得医疗保健的机会.
- ME对默克尔细胞癌 (MCC) 存活率的影响以前是未知的.
研究的目的:
- 确定ME是否与切除MCC的患者的生存率改善有关.
- 分析MCC患者的医疗补助扩张和整体存活率 (OS) 之间的关联.
主要方法:
- 利用国家癌症数据库 (2010-2020年) 对I-III期切除MCC患者.
- 根据国家医疗补助扩张状态分层患者,并使用Kaplan-Meier和Cox回归模型分析整体存活率 (OS).
主要成果:
- 在ME状态下的患者在I-II阶段 (61.4%对58.3%) 和III阶段 (46.9%对44.4%) 的MCC中都有更高的5年生存率.
- ME与改善的生存率 (HR 0.92,P=0.02) 独立相关,即使在扩张状态中具有更多不良特征.
- 在ME后期的诊断也预测了更好的生存率 (HR 0.87,P<0.001).
结论:
- 医疗补助扩张与切除MCC的更好的阶段性生存有关.
- 扩大保险覆盖范围在促进及时的癌症护理方面发挥着至关重要的作用.
- 调查结果强调了医疗保险在改善弱势群体瘤治疗结果方面的重要性.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.9K
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.9K
相关概念视频
Cancer Survival Analysis
626
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
626
Kaplan-Meier Approach
530
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
530
